Connection

ANDREW BADACHHAPE to Cell Line, Tumor

This is a "connection" page, showing publications ANDREW BADACHHAPE has written about Cell Line, Tumor.
Connection Strength

0.179
  1. Biodegradable nanofibrous drug-eluting seed for sustained intratumoral immunotherapy. J Control Release. 2026 07 10; 395:115004.
    View in: PubMed
    Score: 0.034
  2. Investigating the oncogenic role of aberrant EZH2 in hepatoblastoma. Sci Rep. 2026 Feb 06; 16(1).
    View in: PubMed
    Score: 0.034
  3. Dinaciclib improves treatment response in chemoresistant hepatoblastoma. Sci Rep. 2025 Dec 05; 16(1):1410.
    View in: PubMed
    Score: 0.033
  4. HepT1-derived murine models of high-risk hepatoblastoma display vascular invasion, metastasis, and circulating tumor cells. Biol Open. 2022 09 15; 11(9).
    View in: PubMed
    Score: 0.027
  5. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nat Commun. 2022 06 28; 13(1):3728.
    View in: PubMed
    Score: 0.026
  6. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 02 03; 11(1):2967.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.